top of page
Search

Your Price Is Higher. Now What?

Writer: Sarah Sink
Sarah Sink
4 days ago
7 min read

You submitted the proposal.


The technical discussions went well. Your team demonstrated its capabilities, the scope was developed thoughtfully, and you feel good about the opportunity.


Then the sponsor comes back with a familiar response:


“We like your team, but your price is significantly higher than the other CDMOs we’re considering.”


Now what?


The natural reaction is to defend the number.


Explain your capabilities. Highlight your experience. Emphasize your quality systems. Maybe even start thinking about where you could offer a discount.


But before doing any of those things, there’s a much more important question to ask:


Are we actually comparing the same thing?


In CDMO business development, pricing conversations are rarely as straightforward as comparing the totals at the bottom of three proposals.


A lower price does not necessarily mean better value, and a higher price certainly does not guarantee a better solution.


The real opportunity for BD is to help the sponsor understand what is driving the difference and what those differences could mean for their program.



Before You Defend the Price, Understand the Comparison


Imagine your organization submits a proposal for $950,000.


The sponsor tells you another CDMO quoted $750,000.


That’s a $200,000 difference, and it’s significant, but what does that difference actually represent?


Does each proposal include the same development activities?


Are analytical methods included or assumed to be transferred?


How many development iterations are anticipated?


What material requirements are included?


Are stability studies part of the scope?


What assumptions were made about process readiness?


Which activities are optional, and which may become necessary later?


The proposals may all be described as supporting the same development milestone, but that doesn’t mean they contain the same work.


Before discussing discounts or justifying your number, you need to understand whether the comparison itself is valid.


A price comparison without a scope comparison can create a false sense of savings.


And if BD doesn’t understand the difference, how can we expect the sponsor to?



A Lower Quote May Reflect a Different Development Strategy


This is where pricing discussions become more interesting.


Sometimes a competitor’s lower price reflects a genuine advantage.


They may have a more efficient platform, available capacity, relevant experience, or an approach that reduces unnecessary development work.


That’s legitimate value.


Other times, the difference comes from the assumptions behind the proposed work.


One CDMO may recommend additional development activities to reduce downstream risk.


Another may propose moving forward with the information currently available.


Neither approach is automatically wrong.


The right recommendation depends on the molecule, the stage of development, the sponsor’s priorities, and the risks they’re willing and able to accept.


But those differences should be understood.


If one proposal assumes the process is ready for the next stage and another includes work to demonstrate that readiness, the sponsor isn’t simply comparing two prices.


They’re comparing two development strategies.


Your job in BD isn’t to convince the sponsor that your strategy is automatically better. It’s to help them understand why your team recommended it and what trade-offs accompany the alternatives.



The Most Expensive Work May Be the Work Nobody Planned For


One of the biggest commercial risks isn’t necessarily paying more than expected at the beginning.


It’s discovering later that important activities weren’t included in the original scope.


Additional analytical development.


Unexpected process optimization.


Material replacement.


Repeat studies.


Additional manufacturing activities.


Changes to the original scope.


Not every change order indicates a poorly constructed proposal. Drug development is inherently uncertain, and new scientific information can legitimately change the work required.


But there’s a difference between a necessary change driven by new information and additional work that could reasonably have been anticipated during scoping.


That’s an important distinction to communicate.


Sponsors should understand which activities are included, which are conditional, and which assumptions could materially change the budget.


The goal isn’t to eliminate uncertainty. It’s to make the known uncertainties visible before they become expensive surprises.


When your proposal includes activities intended to address identifiable risks, explain those risks.


Don’t simply tell the sponsor your scope is more comprehensive.


Help them understand why that additional work was recommended and what could happen if they choose not to include it.



Stop Defending the Number and Start Asking Better Questions


When a sponsor says, “Your competitor is significantly less expensive,” it’s easy to respond with a list of differentiators.


We have better technology.


We have more experience.


Our quality systems are stronger.


Our people are more knowledgeable.


Those may be meaningful advantages, but they don’t necessarily address the sponsor’s concern.


A more productive conversation starts with understanding what they’re evaluating.


Consider asking:


  • “Are the scopes aligned, or are there differences in the activities being proposed?”

  • “Is your primary concern the overall budget, or are you trying to understand what’s driving the price difference?”

  • “Are there specific activities in our proposal that you don’t believe are necessary at this stage?”

  • “Would it be helpful to walk through our assumptions and identify where there may be opportunities to adjust the approach?”

  • “Are you comparing the initial investment, or are you also considering what each approach could mean for the next development milestone?”


These questions shift the discussion away from defending a number and toward understanding the sponsor’s decision.


Sometimes that conversation reveals that your proposal includes activities the sponsor genuinely needs.


Sometimes it reveals that your team made assumptions worth reconsidering.


And sometimes the competitor really does have a more cost-effective solution.


Strong BD should be comfortable with all three possibilities.



Don’t Confuse More Scope With More Value


This is an important part of commercial judgment.


It’s easy to assume that a more comprehensive proposal is inherently better.


But sponsors don’t necessarily need every available activity.


They need the right activities to accomplish their next milestone while managing risk appropriately.


A sponsor preparing for an early development milestone may have very different priorities from one preparing for late-stage clinical manufacturing.


A company operating with limited capital may need to sequence certain activities differently.


A sponsor with an experienced internal technical team may require less external support than one with limited development resources.


The most valuable proposal isn’t necessarily the one containing the most work.


It’s the one that reflects a thoughtful understanding of the sponsor’s program.


We should be able to explain not only why an activity is included, but why it matters now.


If we can’t do that, we should be willing to revisit the recommendation.


And if the sponsor can achieve the same objective with a smaller scope, that deserves consideration.


Building a long-term partnership sometimes means recommending less today because it’s genuinely the right decision for the program.



Help the Sponsor Evaluate Total Cost, Not Just Initial Price


When your price is higher, one of the most valuable conversations you can have is about the broader implications of the proposed approach.


What happens if additional work becomes necessary?


How could a delay affect the next development milestone?


What internal resources will the sponsor need to dedicate?


Could a different approach reduce future technology transfer requirements?


Does the proposal account for activities that are reasonably likely to become necessary as the program progresses?


These considerations don’t mean every potential risk should be converted into additional scope.


They mean the sponsor should have enough information to understand the potential consequences of the decision.


A lower initial investment may be exactly the right strategy.


But it should be a deliberate choice based on an understanding of the trade-offs, not simply the result of comparing the totals at the bottom of three proposals.


The lowest initial price and the lowest total cost aren’t always the same thing.



Transparency Can Be Your Competitive Advantage


One of the strongest ways to build credibility during a pricing discussion is to be transparent about the assumptions behind your number.


Explain what’s included.


Explain what’s excluded.


Identify where uncertainty exists.


Clarify which activities may be needed depending on the results of earlier work.


And when appropriate, work with your technical team to offer alternative approaches with clear differences in cost, timeline, and risk.


For example, a sponsor may benefit from seeing two options:


Option A: A more limited initial scope designed to answer the most immediate development questions.


Option B: A broader scope that addresses additional technical considerations before the next milestone.


Neither needs to be presented as universally better.


The value comes from helping the sponsor understand what each option accomplishes and what trade-offs accompany it.


And this is where BD and technical need to work together.


BD should understand the sponsor’s commercial priorities, budget considerations, and decision-making process.


The technical team should evaluate the scientific implications of adjusting the proposed approach.


Together, they can develop a recommendation that makes sense for the sponsor.


Good BD doesn’t discount the science to make the numbers work. It works with the experts to find an approach that makes sense scientifically and commercially.



Sometimes the Competitor Really Is the Better Choice


This may not be the most popular point in a BD article, but I think it’s important.


Sometimes another CDMO genuinely has a better fit.


They may have a platform particularly well suited to the molecule.


They may have available capacity that changes the economics.


They may already have relevant experience that reduces the amount of development work required.


Or their proposed approach may align more closely with the sponsor’s immediate priorities.


If that’s the case, trying to convince the sponsor that your higher price must represent greater value doesn’t build credibility.


It can do the opposite.


Our responsibility is to make sure the sponsor understands our proposed approach and the value it provides.


Then we need to respect their decision.


Losing an opportunity doesn’t have to mean losing the relationship.


Being a trusted commercial partner means helping sponsors make informed decisions, even when the decision isn’t in our favor.



The Bigger Picture


There will always be competitors who quote less.


Sometimes the difference will be significant.


And sometimes the sponsor will choose the lower-priced option.


That’s business development.


But before assuming the decision comes down to price, make sure you understand what is actually being compared.


Are the scopes aligned?


Are the assumptions the same?


What risks are being accepted?


What activities could affect the total investment?


And does your proposed approach genuinely align with the sponsor’s development strategy?


Great BD professionals don’t simply defend their organization’s pricing.


They help sponsors understand the decisions behind it.


Because the goal isn’t to convince someone to spend more.


It’s to help them understand what they’re paying for, what they’re not, and what those decisions could mean for their program.


And sometimes, that’s exactly what differentiates you from the competition.



If you want to strengthen how you navigate pricing discussions, communicate commercial value, and help sponsors evaluate proposals beyond the initial number, my course Ask Smarter, Close Sooner was built for business development professionals in CDMOs. It provides practical frameworks for asking better questions, understanding sponsor priorities, and navigating commercial conversations with confidence.


The first few modules are available to preview for free.⁠


For more insights and personalized support in navigating the biotech-CDMO landscape, visit my website: www.yourpharmagirl.com⁠ and follow Your Pharma Girl on LinkedIn⁠.


Whether you need strategic guidance, tailored BD solutions, or expert advice on building lasting partnerships, I am here to help you and your team succeed at every stage of development.

 
 
 

Comments


bottom of page